prikaz prve stranice dokumenta Miller Fisher syndrome following Pfizer COVID-19 vaccine
  Download
PDF 426.66 KB
Scientific paper - Case study
Miller Fisher syndrome following Pfizer COVID-19 vaccine
Neurological Sciences, 43 (2022), 3; 1495-1497. https://doi.org/10.1007/s10072-021-05776-0
Abičić, Ana; Adamec, Ivan; Habek, Mario

Linked objects
COVID-19 | Virtual collection
Cite this document

Abičić, A., Adamec, I. & Habek, M. (2022). Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurological Sciences, 43. (3), 1495-1497. doi: 10.1007/s10072-021-05776-0

Abičić, Ana, et al. "Miller Fisher syndrome following Pfizer COVID-19 vaccine." Neurological Sciences, vol. 43, no. 3, 2022, pp. 1495-1497. https://doi.org/10.1007/s10072-021-05776-0

Abičić, Ana, Ivan Adamec and Mario Habek. "Miller Fisher syndrome following Pfizer COVID-19 vaccine." Neurological Sciences 43, no. 3 (2022): 1495-1497. https://doi.org/10.1007/s10072-021-05776-0

Abičić, A., Adamec, I. and Habek, M. (2022) 'Miller Fisher syndrome following Pfizer COVID-19 vaccine', Neurological Sciences, 43(3), pp. 1495-1497. doi: 10.1007/s10072-021-05776-0

Abičić A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurological Sciences [Internet]. 2022 March [cited 2024 April 13];43(3):1495-1497. doi: 10.1007/s10072-021-05776-0

A. Abičić, I. Adamec and M. Habek, "Miller Fisher syndrome following Pfizer COVID-19 vaccine", Neurological Sciences, vol. 43, no. 3, pp. 1495-1497, March 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:851869. [Accessed: 13 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Miller Fisher syndrome following Pfizer COVID-19 vaccine
AuthorAna Abičić
AuthorIvan Adamec
AuthorMario Habek
Author's institutionUniversity of Zagreb
School of Medicine
(Croatian Institiute for Brain Research)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Introduction: Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barre syndrome characterized by ataxia, areflexia, and ophthalmoplegia. We present a case of MFS following Pfizer COVID-19 vaccine. ----- Case presentation: A previously healthy 24-year-old female presented with binocular horizontal diplopia 18 days after receiving the first dose of Pfizer COVID-19 vaccine (Comirnaty®). Anti-ganglioside testing revealed positive anti-GQ1b antibodies. Intravenous immunoglobulins were administered, in a dose of 2 g per kg of body weight over 5 days. On a follow-up exam 3 weeks after the treatment, clinical improvement was noted with normal bulbomotor examination. ----- Conclusion: Patients with acute ophthalmoplegia occurring after COVID-19 vaccination should be screened for the presence of anti-GQ1b antibody. If the antibody is present, intravenous immunoglobulin should be administered as it may hasten clinical improvement.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleNeurological Sciences
Numberingvol. 43, no. 3, pp. 1495-1497
p-ISSN1590-1874
e-ISSN1590-3478
DOIhttps://doi.org/10.1007/s10072-021-05776-0
URN:NBNurn:nbn:hr:105:851869
Publication2022-03
Document URLhttps://link.springer.com/10.1007/s10072-021-05776-0
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-03-09 09:00:32